ArticleInfection and immunity2012
Progressive cross-reactivity in IgE responses: an explanation for the slow development of human immunity to schistosomiasis?
Article in Infection and immunity, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Effects of Schistosoma haematobium infection and treatment on the systemic and mucosal immune phenotype, gene expression and microbiome: A systematic review.PLoS neglected tropical diseases · 2024Pooled it
- Host determinants of reinfection with schistosomes in humans: a systematic review and meta-analysis.PLoS neglected tropical diseases · 2014Pooled it
- Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt.The American journal of tropical medicine and hygiene · 2014Trial
- Individual and spatial heterogeneity of praziquantel efficacy against Schistosoma mansoni within the context of repeated mass drug administration.Parasites & vectors · 2026Article
- Current water contact and Schistosoma mansoni infection have distinct determinants: a data-driven population-based study in rural Uganda.Nature communications · 2024Article
- Revisiting immunity vs. exposure in schistosomiasis: A mathematical modeling study of delayed concomitant immunity.PNAS nexus · 2024Article
- Schistosome Transgenesis: The Long Road to Success.Biology · 2024Review
- Protective human IgE responses are promoted by comparable life-cycle dependent Tegument Allergen-Like expression in Schistosoma haematobium and Schistosoma mansoni infection.PLoS pathogens · 2023Article
- Human IgE mAbs identify major antigens of parasitic worm infection.The Journal of allergy and clinical immunology · 2022Article
- Increased ShTAL1 IgE responses post-Praziquantel treatment may be associated with a reduced risk to re-infection in a Ghanaian S. haematobium-endemic community.PLoS neglected tropical diseases · 2022Article
- Schistosome immunomodulators.PLoS pathogens · 2021Review
- Immunological Considerations forFrontiers in immunology · 2021Review
- Schistosomes in the Lung: Immunobiology and Opportunity.Frontiers in immunology · 2021Review
- The Genetics of Human Schistosomiasis Infection Intensity and Liver Disease: A Review.Frontiers in immunology · 2021Review
- Schistosomiasis-from immunopathology to vaccines.Seminars in immunopathology · 2020Review
- Current Understanding of Immunity Against Schistosomiasis: Impact on Vaccine and Drug Development.Research and reports in tropical medicine · 2020Review
- Concomitant Immunity and Worm Senescence May Drive Schistosomiasis Epidemiological Patterns: An Eco-Evolutionary Perspective.Frontiers in immunology · 2020Review
- Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment.Frontiers in cellular and infection microbiology · 2020Article
- Schistosoma mansoni venom allergen-like proteins: phylogenetic relationships, stage-specific transcription and tissue localization as predictors of immunological cross-reactivity.International journal for parasitology · 2019Article
- Antibody responses to Schistosoma mansoni schistosomula antigens.Parasite immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
People in regions of Schistosoma mansoni endemicity slowly acquire immunity, but why this takes years to develop is still not clear. It has been associated with increases in parasite-specific IgE, induced, some investigators propose, to antigens exposed during the death of adult worms. These antigens include members of the tegumental-allergen-like protein family (TAL1 to TAL13). Previously, in a group of S. mansoni-infected Ugandan males, we showed that IgE responses to three TALs expressed in worms (TAL1, -3, and -5) became more prevalent with age. Now, in a subcohort we examined associations of these responses with resistance to reinfection and use the data to propose a mechanism for the slow development of immunity. IgE was measured 9 weeks posttreatment and at reinfection at 2 years (n = 144). An anti-TAL5 IgE (herein referred to as TAL5 IgE) response was associated with reduced reinfection even after adjusting for age using regression analysis (geometric mean odds ratio, 0.24; P = 0.016). TAL5 IgE responders were a subset of TAL3 IgE responders, themselves a subset of TAL1 responders. TAL3 IgE and TAL5 IgE were highly cross-reactive, with TAL3 the immunizing antigen and TAL5 the cross-reactive antigen. Transcriptional and translational studies show that TAL3 is most abundant in adult worms and that TAL5 is most abundant in infectious larvae. We propose that in chronic schistosomiasis, older individuals have repeatedly experienced IgE antigens exposed when adult worms die (e.g., TAL3) and that this leads to increasing cross-reactivity with antigens of invading larvae (e.g., TAL5). Progressive accumulation of worm/larvae cross-reactivity could explain the age-dependent immunity observed in areas of endemicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.